502 related articles for article (PubMed ID: 32294407)
1. The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
Mohamed E; Sierra RA; Trillo-Tinoco J; Cao Y; Innamarato P; Payne KK; de Mingo Pulido A; Mandula J; Zhang S; Thevenot P; Biswas S; Abdalla SK; Costich TL; Hänggi K; Anadon CM; Flores ER; Haura EB; Mehrotra S; Pilon-Thomas S; Ruffell B; Munn DH; Cubillos-Ruiz JR; Conejo-Garcia JR; Rodriguez PC
Immunity; 2020 Apr; 52(4):668-682.e7. PubMed ID: 32294407
[TBL] [Abstract][Full Text] [Related]
2. Dual negative roles of C/EBPα in the expansion and pro-tumor functions of MDSCs.
Mackert JR; Qu P; Min Y; Johnson PF; Yang L; Lin PC
Sci Rep; 2017 Oct; 7(1):14048. PubMed ID: 29070836
[TBL] [Abstract][Full Text] [Related]
3. Tumor conditions induce bone marrow expansion of granulocytic, but not monocytic, immunosuppressive leukocytes with increased CXCR2 expression in mice.
Bian Z; Shi L; Venkataramani M; Abdelaal AM; Culpepper C; Kidder K; Liang H; Zen K; Liu Y
Eur J Immunol; 2018 Mar; 48(3):532-542. PubMed ID: 29120053
[TBL] [Abstract][Full Text] [Related]
4. Anti-Jagged Immunotherapy Inhibits MDSCs and Overcomes Tumor-Induced Tolerance.
Sierra RA; Trillo-Tinoco J; Mohamed E; Yu L; Achyut BR; Arbab A; Bradford JW; Osborne BA; Miele L; Rodriguez PC
Cancer Res; 2017 Oct; 77(20):5628-5638. PubMed ID: 28904063
[TBL] [Abstract][Full Text] [Related]
5. Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer.
Cubillos-Ruiz JR; Mohamed E; Rodriguez PC
J Immunother Cancer; 2017; 5():5. PubMed ID: 28105371
[TBL] [Abstract][Full Text] [Related]
6. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
[TBL] [Abstract][Full Text] [Related]
7. AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells.
Trillo-Tinoco J; Sierra RA; Mohamed E; Cao Y; de Mingo-Pulido Á; Gilvary DL; Anadon CM; Costich TL; Wei S; Flores ER; Ruffell B; Conejo-Garcia JR; Rodriguez PC
Cancer Res; 2019 Oct; 79(19):5034-5047. PubMed ID: 31409640
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice.
Zheng Y; Tian X; Wang T; Xia X; Cao F; Tian J; Xu P; Ma J; Xu H; Wang S
Mol Cancer; 2019 Mar; 18(1):61. PubMed ID: 30925926
[TBL] [Abstract][Full Text] [Related]
9. Critical role of PPARγ in myeloid-derived suppressor cell-stimulated cancer cell proliferation and metastasis.
Zhao T; Du H; Blum JS; Yan C
Oncotarget; 2016 Jan; 7(2):1529-43. PubMed ID: 26625314
[TBL] [Abstract][Full Text] [Related]
10. ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
Cao Y; Trillo-Tinoco J; Sierra RA; Anadon C; Dai W; Mohamed E; Cen L; Costich TL; Magliocco A; Marchion D; Klar R; Michel S; Jaschinski F; Reich RR; Mehrotra S; Cubillos-Ruiz JR; Munn DH; Conejo-Garcia JR; Rodriguez PC
Nat Commun; 2019 Mar; 10(1):1280. PubMed ID: 30894532
[TBL] [Abstract][Full Text] [Related]
11. Reducing Stress PERKs up Anti-tumor Immunity.
Charbonneau ME; O'Riordan MXD
Immunity; 2020 Apr; 52(4):575-577. PubMed ID: 32294402
[TBL] [Abstract][Full Text] [Related]
12. EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells.
Huang S; Wang Z; Zhou J; Huang J; Zhou L; Luo J; Wan YY; Long H; Zhu B
Cancer Res; 2019 Apr; 79(8):2009-2020. PubMed ID: 30737232
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
Tengesdal IW; Menon DR; Osborne DG; Neff CP; Powers NE; Gamboni F; Mauro AG; D'Alessandro A; Stefanoni D; Henen MA; Mills TS; De Graaf DM; Azam T; Vogeli B; Palmer BE; Pietras EM; DeGregori J; Tan AC; Joosten LAB; Fujita M; Dinarello CA; Marchetti C
Proc Natl Acad Sci U S A; 2021 Mar; 118(10):. PubMed ID: 33649199
[TBL] [Abstract][Full Text] [Related]
14. Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment.
Cekic C; Day YJ; Sag D; Linden J
Cancer Res; 2014 Dec; 74(24):7250-9. PubMed ID: 25377469
[TBL] [Abstract][Full Text] [Related]
15. Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses.
Mandula JK; Chang S; Mohamed E; Jimenez R; Sierra-Mondragon RA; Chang DC; Obermayer AN; Moran-Segura CM; Das S; Vazquez-Martinez JA; Prieto K; Chen A; Smalley KSM; Czerniecki B; Forsyth P; Koya RC; Ruffell B; Cubillos-Ruiz JR; Munn DH; Shaw TI; Conejo-Garcia JR; Rodriguez PC
Cancer Cell; 2022 Oct; 40(10):1145-1160.e9. PubMed ID: 36150390
[TBL] [Abstract][Full Text] [Related]
16. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
[TBL] [Abstract][Full Text] [Related]
17. Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy.
Lan J; Li R; Yin LM; Deng L; Gui J; Chen BQ; Zhou L; Meng MB; Huang QR; Mo XM; Wei YQ; Lu B; Dicker A; Xue JX; Lu Y
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):74-87. PubMed ID: 29619980
[TBL] [Abstract][Full Text] [Related]
18. PERK induces resistance to cell death elicited by endoplasmic reticulum stress and chemotherapy.
Salaroglio IC; Panada E; Moiso E; Buondonno I; Provero P; Rubinstein M; Kopecka J; Riganti C
Mol Cancer; 2017 May; 16(1):91. PubMed ID: 28499449
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of PKR-like ER Kinase (PERK) Signaling Selectively Controls Endoplasmic Reticulum Stress-induced Inflammation Without Compromising Immunological Responses.
Guthrie LN; Abiraman K; Plyler ES; Sprenkle NT; Gibson SA; McFarland BC; Rajbhandari R; Rowse AL; Benveniste EN; Meares GP
J Biol Chem; 2016 Jul; 291(30):15830-40. PubMed ID: 27226638
[TBL] [Abstract][Full Text] [Related]
20. Type I IFN protects cancer cells from CD8+ T cell-mediated cytotoxicity after radiation.
Chen J; Cao Y; Markelc B; Kaeppler J; Vermeer JA; Muschel RJ
J Clin Invest; 2019 Oct; 129(10):4224-4238. PubMed ID: 31483286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
